{
    "ticker": "PSNL",
    "name": "Poseida Therapeutics, Inc.",
    "description": "Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative cell and gene therapies for patients with cancer and other serious diseases. Founded in 2014 and headquartered in San Diego, California, Poseida specializes in harnessing the power of the immune system to treat cancer, utilizing its proprietary technologies including the PiggyBac gene delivery system, which enables the precise and efficient insertion of genes into a patient's cells. This technology enhances the efficacy and safety of therapies by allowing for the selective targeting of cancer cells. Poseida is committed to advancing its pipeline of product candidates, which includes P-BCMA-101 for the treatment of multiple myeloma, and P-PSMA-101 for prostate cancer. The company aims to develop transformative therapies that can significantly improve the lives of patients through durable responses and reduced toxicity. Poseida's multidisciplinary team of experts in gene editing, immunology, and cell therapy collaborates closely to innovate and deliver next-generation treatments that address unmet medical needs. With a robust clinical development strategy, Poseida is poised to lead in the field of advanced therapies, contributing to the future of personalized medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2014",
    "website": "https://poseida.com",
    "ceo": "Mark G. H. Allen",
    "social_media": {
        "twitter": "https://twitter.com/PoseidaTx",
        "linkedin": "https://www.linkedin.com/company/poseida-therapeutics"
    },
    "investor_relations": "https://investors.poseida.com",
    "key_executives": [
        {
            "name": "Mark G. H. Allen",
            "position": "CEO"
        },
        {
            "name": "M. Scott Koenig",
            "position": "President and COO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "P-BCMA-101",
                "P-PSMA-101"
            ]
        },
        {
            "category": "Gene Therapies",
            "products": [
                "PiggyBac Gene Delivery System"
            ]
        }
    ],
    "seo": {
        "meta_title": "Poseida Therapeutics, Inc. | Innovative Cell and Gene Therapies",
        "meta_description": "Explore Poseida Therapeutics, Inc., a leading biopharmaceutical company specializing in advanced cell and gene therapies for cancer treatment. Discover our innovative technologies and pipeline.",
        "keywords": [
            "Poseida Therapeutics",
            "Cell Therapy",
            "Gene Therapy",
            "Biotechnology",
            "Cancer Treatment",
            "P-BCMA-101",
            "P-PSMA-101"
        ]
    },
    "faq": [
        {
            "question": "What is Poseida Therapeutics known for?",
            "answer": "Poseida Therapeutics is known for developing innovative cell and gene therapies for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Poseida Therapeutics?",
            "answer": "Mark G. H. Allen is the CEO of Poseida Therapeutics, Inc."
        },
        {
            "question": "Where is Poseida headquartered?",
            "answer": "Poseida is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Poseida's main products?",
            "answer": "Poseida's main products include P-BCMA-101 and P-PSMA-101, focusing on multiple myeloma and prostate cancer, respectively."
        },
        {
            "question": "When was Poseida Therapeutics founded?",
            "answer": "Poseida Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "BLUE",
        "ZIOP"
    ],
    "related_stocks": [
        "BMY",
        "JNJ",
        "AMGN",
        "GILD"
    ]
}